Alivus Life Sciences FY26 Performance

Revenue FY26: ₹2,551.83 crore
Net Profit FY26: ₹564.48 crore

Reader Takeaway: Strong profit growth driven by API+ strategy, but watch geopolitical risks.

What just happened

Alivus Life Sciences Ltd announced its financial results for the fiscal year 2025-26, reporting a revenue of ₹2,551.83 crore, marking a 6.9% increase compared to ₹2,386.88 crore in the previous year. The net profit after tax (PAT) saw a significant jump of 16.2%, reaching ₹564.48 crore from ₹485.63 crore in FY25. Earnings per share (EPS) grew by 16.1% to ₹45.99.

Why this matters

The results indicate robust growth and profitability for Alivus Life Sciences. The company maintained a net debt-free balance sheet, funded by internal accruals, which provides financial stability. An EBITDA margin expansion of 360 basis points to 33.6% highlights improved operational efficiency.

The backstory

Alivus Life Sciences' 'API+' strategy, focusing on adjacent capabilities like flow chemistry and high-potent APIs (HPAPI), is proving effective. The Contract Development and Manufacturing Organization (CDMO) business emerged as a key growth driver, growing by 18% year-on-year.

What changes now

The company plans significant capital expenditure for FY27, estimated at ₹540 crore. This includes a new R&D facility in Taloja and a greenfield project in Solapur, to be funded entirely by internal cash flows. Manufacturing capacity is set to increase from 1,424 KL in FY26 to 2,690 KL by FY29.

The Board has recommended a final dividend of 250% (₹5 per equity share of face value ₹2 each) for FY26.

Risks to watch

A flash fire incident occurred at the Ankleshwar plant in September 2025, resulting in compensation costs of ₹29 lakh. Ongoing geopolitical shifts and regulatory changes could impact future margin stability.

Peer comparison

(No peer comparison data provided in the filing.)

Context metrics (time-bound)

• Revenue FY26: ₹2,551.83 crore (up 6.9% YoY)
• Net Profit FY26: ₹564.48 crore (up 16.2% YoY)
• EBITDA Margin: 33.6% (up 360 bps)
• CDMO Growth: 18% YoY
• Reactor Capacity FY26: 1,424 KL
• Reactor Capacity FY29 Target: 2,690 KL
• FY27 Capex: ₹540 crore
• Dividend: ₹5 per share

What to track next

Investors will be keen to observe the progress of the new R&D facility and the Solapur greenfield project. Monitoring the company's ability to manage geopolitical and regulatory challenges will also be crucial.